Ipsc-derived pancreatic progenitors

Ipsc-derived pancreatic progenitors has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest paper, Oct 26, 2026: “Combined B2M Knockout and Alginate Encapsulation Reduces Immune Rejection of iPSC-Derived Pancreatic Progenitors”.

Intervention

1 paper studies it1 findingUpdated

1 new paper in 30 daysSee all 1 papers on ipsc-derived pancreatic progenitors

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country.

Mice: a single group. Cells, worms or flies and humans: nothing yet.
  • 1 lab in 1 country
  • Funder: Russian Science Foundation
  • Animals1

What did studies of ipsc-derived pancreatic progenitors find?

1

Studies of ipsc-derived pancreatic progenitors measured one outcome, fibrotic capsule thickness.

Fibrotic capsule thickness

downin rats1

1 study
  1. Ipsc-derived pancreatic progenitors decrease fibrotic capsule thickness in rats Following transplantation.

    “IPS-∆B2M-PP implants exhibited the thinnest fibrotic capsules and minimal lymphocytic infiltration.”

    AnimalsFollowing transplantationB2M-knockout, alginate-encapsulatedomentum

    Combined B2M Knockout and Alginate Encapsulation Reduces Immune Rejection of iPSC-Derived Pancreatic Progenitors

    Cells

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 1Nov 2026: 01 paper in 12 months